Tekla Life Sciences Investors:HQL

    Manage Alerts

    Overview

    As of 9/25/2020

     Share
    Price
    NAVPremium/
    Discount
    Current$17.32$19.97-13.27%
    52 Wk Avg$16.95$19.20-11.73%
    52 Wk High$19.28$22.05-8.60%
    52 Wk Low$11.45$15.12-22.61%
    Regular Distribution TypeManaged Distribution
    Distribution Rate9.47%
    Distribution Amount$0.4100
    Distribution FrequencyQuarterly
    Past performance is no guarantee of future results.

    Basic Information

    Investment Objective

    To seek long-term capital appreciation by investing primarily in equity and equity related securities of US and non-US companies principally engaged in the development, production or distribution of products or services related to scientific advances in healthcare, agriculture and environmental management. Under normal market conditions, the Trust will invest at least 65% of its total assets in securities of Life Sciences Companies. The Trust may also invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale and up to 25% in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan.

    Capital Structure

    As of 9/25/2020

    Total Investment Exposure:$472.614M
    Total Common Assets:$472.614M
    Common Shares Outstanding:23,666,218
    Annual Expense Ratios

    As of 9/30/2019

      Per Common Share
    Management Fees1.02%
    Other Expenses:0.27%
    Baseline Expense: N/A
    Interest Expense:N/A
    Total: 1.29%
    Fund Management

    Fund Sponsor
    Hambrecht & Quist

    Portfolio Managers
    Daniel R. Omstead

    Basics
    Category: Equity-Sector Equity
    Ticker: HQL
    NAV Ticker: XHQLX
    Average Daily Volume (shares): 103,878
    Average Daily Volume (USD): $1.731M
    Inception Date: 5/8/1992
    Inception Share Price: $15.00
    Inception NAV: $13.95
    Tender Offer: No
    Term: No
    Fiscal Year End: September 30
    Third Party Links & Reports

    Distributions

    As of 9/25/2020

    Past performance is no guarantee of future results.
    Distribution History

    Enter declared start and end dates to display distribution history below. Income, Long Gain, Short Gain and ROC breakdowns will only be shown for the past year.

    Declared Date Payable Date Ex Date Distrib Amount Income Long Gain Short Gain ROC

    *Indicates a Special Distribution: A distribution disbursed in addition to the normal distributions paid out by the company.

    Key Information Regarding Distributions
    Avg. Earnings Per Share:
    As of 3/31/2020
    -$0.0198
    Annualized Distribution Rate on NAV:
    As of 9/25/2020
    8.21%
    Total Return on NAV (12 months):
    As of 9/25/2020
    26.62%
    Avg. Portfolio Coupon:
    As of 9/25/2020
    8.00%
    Total % Portfolio Effectively Leveraged:
    As of 9/25/2020
    0.00%

    Pricing Information

    Premium/Discount Information
    Past performance is no guarantee of future results.
    Premium/Discount Information

    As of 9/25/2020

    PeriodAvg Discount
    6 Month-12.68%
    1 Year-11.73%
    3 Year-7.42%
    5 Year-5.58%
    Z-Score

    As of 9/25/2020

    PeriodZStat
    3 Month-1.03
    6 Month-0.79
    1 Year-0.78
    Pricing History
    Date NAV Premium / Discount

    Performance

    Calendar Year Total Returns

    As of 8/31/2020
    Category: Morningstar US CEF Sector Equity

    Past 20 Years

    Return YearPriceNAVCategory - PriceCategory - NAV
    YTD9.28%9.44%-7.71%-5.77%
    201925.51%26.46%26.64%22.38%
    2018-14.41%-7.43%-12.35%-9.96%
    201725.54%19.35%18.18%12.88%
    2016-19.49%-16.30%17.45%14.67%
    20155.87%6.90%-15.98%-12.75%
    201433.63%32.09%5.16%4.65%
    201352.19%51.98%16.34%17.44%
    201237.16%27.20%12.53%11.75%
    201120.67%16.32%-1.05%0.79%
    201020.45%11.76%20.02%17.83%
    200914.78%11.24%50.36%35.04%
    2008-27.85%-23.75%-42.07%-39.30%
    20077.24%16.90%  
    2006-4.92%-1.07%  
    200512.00%9.09%  
    200410.96%6.31%  
    200342.06%24.97%  
    2002-36.09%-35.74%  
    200114.01%1.02%  
    200028.24%46.57%  
    Past performance is no guarantee of future results.
    Annualized Total Returns

    Returns for periods less than one year are cumulative rather than annualized

    As of 8/31/2020
    Category: Morningstar US CEF Sector Equity

    Past performance is no guarantee of future results.

    Portfolio Characteristics

    Portfolio Characteristics
    Average Coupon:
    As of 9/25/2020
    8.00%
    Number of Holdings:
    As of 6/30/2020
    172
    Annual Portfolio Turnover:
    As of 9/30/2019
    43.78%
    Asset Allocation

    As of 6/30/2020 reported by Fund Sponsor

    Top Sectors

    As of 6/30/2020 reported by Fund Sponsor

    Sector%Portfolio
    Healthcare92.83%
    Defensive (Super Sector)92.83%
    Corporate (Super Sector)4.81%
    Preferred Stock4.75%
    Cash Equivalents (Super Sector)1.29%
    Cash Equivalents1.29%
    Corporate Bond0.07%
    Top Holdings

    As of 6/30/2020 reported by Fund Sponsor

    HoldingValue% Portfolio
    Vertex Pharmaceuticals Inc$39.23M8.01%
    Amgen Inc$38.19M7.80%
    Regeneron Pharmaceuticals Inc$35.86M7.32%
    Gilead Sciences Inc$35.14M7.17%
    Illumina Inc$23.07M4.71%
    Biogen Inc$17.74M3.62%
    Seattle Genetics Inc$14.82M3.02%
    Alexion Pharmaceuticals Inc$12.61M2.57%
    Moderna Inc$11.20M2.29%
    Biomarin Pharmaceutical Inc$11.02M2.25%
    Maturity Breakdown

    As of 6/30/2020 reported by Fund Sponsor

    Closed-end fund historical distribution sources have included net investment income, realized gains, and return of capital. For more detailed information on the distributions of a specific fund, please visit the sponsor's website.

    NOTES:

    Distribution type sourced from Morningstar. In general, managed distributions may be sourced from net investment income, realized gains and return of capital. CEFConnect.com does not undertake to disclose specific information about closed-end fund distribution sources. For specific information about a fund's distribution sources, visit the fund sponsor's website.

    The following information applies to closed-end funds in general: Fund shares are not guaranteed or endorsed by any bank or other insured depository institution, and are not federally insured by the Federal Deposit Insurance Corporation. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. There can be no assurance that fund objectives will be achieved. Closed-end funds frequently trade at a discount to their net asset value. NAV returns are net of fund expenses, and assume reinvestment of distributions.

    EWB-1014244PR-E1119W